Shijiazhuang No. 4 Pharmaceutical Co., Ltd. is again ranking top 50 in China Chemical Drug R&D Strength

Shijiazhuang No. 4 Pharmaceutical Co., Ltd. is ranking top 50 in China Chemical Drug R&D Strength Once Again

On September 18, at the 2021 Conference on High Quality Development of Health Industry and the sixth Summit for China Pharmaceutical R&D Innovation (PDI) held in Chongqing, the list of 2021 Chinese Chemical pharmaceutical R&D Strength TOP100 was announced, and Shijiazhuang No. 4 Pharmaceutical Co., Ltd. ranked 44th, once again ranked among the top 50 chemical pharmaceutical R&D strength in China.  

R&d investment is one of the important indicators of innovation capacity. According to Frost&Sullivan data, R&D investment of innovative pharmaceutical enterprises has continued to grow in the past five years. From 2016 to 2020, the total R&D investment in China has increased from 11.9 billion US dollars to 27 billion US dollars, with a compound annual growth rate of 22.7%.  Twenty-four companies on the list spent more than 500 million yuan on R&D in 2020, while eight spent more than 1 billion yuan on R&D.  

With the policy implementation execute, the pharmaceutical industry market is facing a constant adjustment and differentiation, competitive situation from production as the core to research and development ability and drug innovation as the core, mainly on research and development of innovative enterprises will usher in unprecedented opportunities for development.